Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) will present new research at the SPIE Photonics West conference in San Francisco, showcasing the effectiveness of its Steriwave nasal photodisinfection system.
The study, involving 35 healthy volunteers, showed that photodisinfection significantly reduces nasal pathogens without causing long-term harm to the nasal microbiome.
The Steriwave system, a non-selective, short-acting method, allows for rapid microbiome recovery within a week post-treatment.
Dr Caetano Sabino, Ondine's director of research and development, will further discuss these findings on 30 January.